PACAP-38 (31-38), human, mouse, rat

PACAP-38 (31-38), human, mouse, rat is a PAC1 receptor activator and increases the α-secretase activity. PACAP-38 (31-38), human, mouse, rat elevates cytosolic Ca2+, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR) . PACAP-38 (31-38), human, mouse, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP-38 (31-38), human, mouse, rat can be used for neurotrophic and neuroprotective research[1][2][3].

Product Specifications

CAS Number

[138764-85-9]

UNSPSC

12352209

Target

Calcium Channel; EGFR; ERK; Reactive Oxygen Species (ROS)

Type

Peptides

Related Pathways

Immunology/Inflammation; JAK/STAT Signaling; MAPK/ERK Pathway; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling; NF-κB; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/pacap-38-31-38-human-mouse-rat.html

Purity

98.99

Solubility

H2O : 100 mg/mL (ultrasonic)

Smiles

NCCCC[C@@H](C(N)=O)NC([C@H](CC(N)=O)NC([C@H](CCCCN)NC([C@H](C(C)C)NC([C@H](CCCNC(N)=N)NC([C@H](CCC(N)=O)NC([C@H](CCCCN)NC([C@H](CC1=CC=C(O)C=C1)N)=O)=O)=O)=O)=O)=O)=O

Molecular Formula

C47H83N17O11

Molecular Weight

1062.27

References & Citations

[1]Moody TW, et, al. PAC1 regulates receptor tyrosine kinase transactivation in a reactive oxygen species-dependent manner. Peptides. 2019 Oct;120:170017.|[2]Kojro E, et, al. The neuropeptide PACAP promotes the alpha-secretase pathway for processing the Alzheimer amyloid precursor protein. FASEB J. 2006 Mar;20 (3) :512-4.|[3]Braas KM, et, al. Pituitary adenylate cyclase-activating polypeptides, PACAP-38 and PACAP-27, regulation of sympathetic neuron catecholamine, and neuropeptide Y expression through activation of type I PACAP/VIP receptor isoforms. Ann N Y Acad Sci. 1996 Dec 26;805:204-16; discussion 217-8.